Wall Street analysts predict that Constellation Pharmaceuticals Inc (NASDAQ:CNST) will report earnings of ($0.81) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Constellation Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.83) and the highest estimate coming in at ($0.80). Constellation Pharmaceuticals also posted earnings per share of ($0.81) in the same quarter last year. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 14th.
On average, analysts expect that Constellation Pharmaceuticals will report full year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.27) to ($2.89). For the next fiscal year, analysts anticipate that the firm will post earnings of ($3.17) per share, with EPS estimates ranging from ($4.05) to ($2.10). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Constellation Pharmaceuticals.
Constellation Pharmaceuticals (NASDAQ:CNST) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80).
Several research firms have commented on CNST. Zacks Investment Research lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. ValuEngine raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Constellation Pharmaceuticals in a research report on Wednesday, June 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.00.
NASDAQ:CNST traded down $0.42 during mid-day trading on Friday, hitting $7.11. The company had a trading volume of 461 shares, compared to its average volume of 28,368. The business has a fifty day simple moving average of $9.11 and a 200-day simple moving average of $10.42. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.44. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $14.04. The firm has a market capitalization of $198.58 million and a price-to-earnings ratio of -1.42.
Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Constellation Pharmaceuticals by 30.7% in the second quarter. Vanguard Group Inc. now owns 530,331 shares of the company’s stock worth $6,513,000 after buying an additional 124,591 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Constellation Pharmaceuticals during the second quarter worth about $329,000. BlackRock Inc. grew its holdings in Constellation Pharmaceuticals by 13.0% during the second quarter. BlackRock Inc. now owns 820,432 shares of the company’s stock worth $10,074,000 after acquiring an additional 94,107 shares during the period. Northern Trust Corp grew its holdings in Constellation Pharmaceuticals by 12.7% during the second quarter. Northern Trust Corp now owns 146,358 shares of the company’s stock worth $1,797,000 after acquiring an additional 16,548 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Constellation Pharmaceuticals during the second quarter worth about $61,000. Institutional investors own 64.14% of the company’s stock.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
See Also: 52-Week High/Low
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.